Drug Details
General Information of the Drug (ID: DR2889) | ||||
---|---|---|---|---|
Name |
Tolfenamic acid
|
|||
Synonyms |
Clotam; Tolfedine; 2-[(3-Chloro-2-methylphenyl)amino]benzoic Acid; N-(3-Chloro-2-methylphenyl)anthranilic acid; GEA 6414; Acido tolfenamico; Acide tolfenamique; Acidum tolfenamicum; 2-((3-Chloro-2-methylphenyl)amino)benzoic acid; 2-(3-Chloro-2-methylanilino)benzoic acid; N-(2-Methyl-3-chlorophenyl)anthranilic acid; UNII-3G943U18KM; N-(3-Chloro-o-tolyl)-anthranilic acid; Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]-; Anthranilic acid, N-(3-chloro-o-tolyl)-; N-(3-Chloro-ortho-tolyl) anthranilic acid; CHEBI:32243; 3G943U18KM; NCGC00016705-05; Bifenac; CAS-13710-19-5; DSSTox_CID_25409; DSSTox_RID_80860; DSSTox_GSID_45409; Tolfine; tolfenamic-acid; 2-([3-Chloro-2-methylphenyl]amino)benzoic acid; SR-01000000102; N-(3-Chloro-o-tolyl)anthranilic acid; Tolfenamic; Acide tolfenamique [INN-French]; Acido tolfenamico [INN-Spanish]; Acidum tolfenamicum [INN-Latin]; Tolfenamic acid [INN:BAN:JAN]; Prestwick_579; EINECS 237-264-3; Clotam (TN); TOLFENAMICACID; BRN 0657821; Spectrum_001263; ACMC-209cat; Tolfenamic Acid-13C6; Tolfenamic acid, NSAID; Prestwick0_000205; Prestwick1_000205; Prestwick2_000205; Prestwick3_000205; Spectrum2_001446; Spectrum3_001762; Spectrum4_000238; Spectrum5_001143; Oprea1_692996; SCHEMBL25190; Tolfenamic acid (JAN/INN); BSPBio_000189; BSPBio_003223; KBioGR_000935; KBioSS_001743; flufenamic acid analogue, 32; MLS000028531; BIDD:GT0343; SPECTRUM1501198; SPBio_001311; SPBio_002110; BPBio1_000209; CHEMBL121626; cid_610479; GTPL8769; ZINC2188; DTXSID1045409; BDBM35905; KBio2_001743; KBio2_004311; KBio2_006879; KBio3_002723; YEZNLOUZAIOMLT-UHFFFAOYSA-; HMS1568J11; HMS1921P13; HMS2090D04; HMS2095J11; HMS2230J13; HMS3370A02; HMS3651E06; HMS3712J11; HMS3884M16; Pharmakon1600-01501198; HY-B0335; Tox21_110570; ANW-20211; CCG-39189; MFCD00133865; NSC757873; s1959; SBB058187; AKOS012836098; Tox21_110570_1; 2-(3-Chloro-o-toluidino)benzoic Acid; DB09216; MCULE-9901889833; NSC-757873; 2(3-Chloro-2-methylanilino)benzoic acid; NCGC00016705-01; NCGC00016705-02; NCGC00016705-03; NCGC00016705-04; NCGC00016705-06; NCGC00016705-07; NCGC00016705-10; NCGC00022587-03; NCGC00022587-04; NCGC00022587-05; AK305709; AS-13748; DA-11289; n-(3-chloro-ortho-tolyl)anthranilic acid; SMR000058289; SBI-0051687.P002; AB0032595; 2-(3-Chloro-2-methylanilino)benzoic acid #; AB00052244; FT-0652603; ST51015128; SW196753-3; UNM000001237003; X5948; 2-(3-chloro-2-methylphenylamino)benzoic acid; D01183; J10240; Q59412; AB00052244-15; AB00052244_16; AB00052244_17; A807198; Benzoic acid, 2-(3-chloro-2-methylphenylamino)-; 2-[(3-chloranyl-2-methyl-phenyl)amino]benzoic acid; J-006962; SR-01000000102-2; SR-01000000102-3; Tolfenamic acid, VETRANAL(TM), analytical standard; BRD-K50133271-001-05-4; BRD-K50133271-001-10-4; Benzoic acid, 2-((3-chloro-2-methylphenyl)amino)- (9CI); Tolfenamic acid, European Pharmacopoeia (EP) Reference Standard; Tolfenamic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Pancreatic cancer [ICD-11: 2C10] | Investigative | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C14H12ClNO2
|
|||
PubChem CID | ||||
Canonical SMILES |
CC1=C(C=CC=C1Cl)NC2=CC=CC=C2C(=O)O
|
|||
InChI |
1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)
|
|||
InChIKey |
YEZNLOUZAIOMLT-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 13710-19-5
|
|||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Activity | CASP7 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | PSG1 | Molecule Info | |||
Biological
Regulation |
Induction | Loss of mitochondrial membrane potential | ||||
Up-regulation | ROS generation | |||||
In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Thioridazine plus curcumin induces proteasome activity by up-regulating PSMA5 expression via NOX4-mediated ROS production and that down-regulation of c-FLIP and Mcl-1 expression post-translationally is involved in apoptosis. | |||||
Vincristine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
In-vitro Model | Daoy | CVCL_1167 | Medulloblastoma | Homo sapiens | ||
D283 Med | CVCL_1155 | Medulloblastoma | Homo sapiens | |||
Experimental
Result(s) |
Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | DNA-binding factor KBF1 (p105) | Molecule Info | [4] | |
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | Ras signaling pathway | |||
3 | cAMP signaling pathway | |||
4 | Chemokine signaling pathway | |||
5 | NF-kappa B signaling pathway | |||
6 | HIF-1 signaling pathway | |||
7 | Sphingolipid signaling pathway | |||
8 | PI3K-Akt signaling pathway | |||
9 | Apoptosis | |||
10 | Osteoclast differentiation | |||
11 | Toll-like receptor signaling pathway | |||
12 | NOD-like receptor signaling pathway | |||
13 | RIG-I-like receptor signaling pathway | |||
14 | Cytosolic DNA-sensing pathway | |||
15 | T cell receptor signaling pathway | |||
16 | B cell receptor signaling pathway | |||
17 | TNF signaling pathway | |||
18 | Neurotrophin signaling pathway | |||
19 | Prolactin signaling pathway | |||
20 | Adipocytokine signaling pathway | |||
21 | Non-alcoholic fatty liver disease (NAFLD) | |||
22 | Cocaine addiction | |||
23 | Epithelial cell signaling in Helicobacter pylori infection | |||
24 | Shigellosis | |||
25 | Salmonella infection | |||
26 | Pertussis | |||
27 | Legionellosis | |||
28 | Leishmaniasis | |||
29 | Chagas disease (American trypanosomiasis) | |||
30 | Toxoplasmosis | |||
31 | Amoebiasis | |||
32 | Tuberculosis | |||
33 | Hepatitis C | |||
34 | Hepatitis B | |||
35 | Measles | |||
36 | Influenza A | |||
37 | HTLV-I infection | |||
38 | Herpes simplex infection | |||
39 | Epstein-Barr virus infection | |||
40 | Pathways in cancer | |||
41 | Transcriptional misregulation in cancer | |||
42 | Viral carcinogenesis | |||
43 | MicroRNAs in cancer | |||
44 | Pancreatic cancer | |||
45 | Prostate cancer | |||
46 | Chronic myeloid leukemia | |||
47 | Acute myeloid leukemia | |||
48 | Small cell lung cancer | |||
49 | Inflammatory bowel disease (IBD) | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
2 | IL1 Signaling Pathway | |||
3 | TCR Signaling Pathway | |||
4 | IL2 Signaling Pathway | |||
5 | TNFalpha Signaling Pathway | |||
6 | Leptin Signaling Pathway | |||
Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
2 | T cell activation | |||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
2 | BCR signaling pathway | |||
3 | LPA receptor mediated events | |||
4 | Atypical NF-kappaB pathway | |||
5 | Canonical NF-kappaB pathway | |||
6 | CD40/CD40L signaling | |||
7 | IL12-mediated signaling events | |||
8 | Alternative NF-kappaB pathway | |||
9 | Osteopontin-mediated events | |||
10 | Angiopoietin receptor Tie2-mediated signaling | |||
11 | Signaling events mediated by HDAC Class I | |||
12 | Regulation of Telomerase | |||
13 | IL1-mediated signaling events | |||
14 | Glucocorticoid receptor regulatory network | |||
15 | TNF receptor signaling pathway | |||
16 | IL2 signaling events mediated by PI3K | |||
17 | Ceramide signaling pathway | |||
18 | amb2 Integrin signaling | |||
19 | IL23-mediated signaling events | |||
20 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
21 | EPO signaling pathway | |||
Reactome | Activation of NF-kappaB in B cells | Click to Show/Hide | ||
2 | RIP-mediated NFkB activation via ZBP1 | |||
3 | Regulated proteolysis of p75NTR | |||
4 | NF-kB is activated and signals survival | |||
5 | Senescence-Associated Secretory Phenotype (SASP) | |||
6 | FCERI mediated NF-kB activation | |||
7 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||
8 | Transcriptional regulation of white adipocyte differentiation | |||
9 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
10 | Interleukin-1 processing | |||
11 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||
12 | IkBA variant leads to EDA-ID | |||
13 | CLEC7A (Dectin-1) signaling | |||
14 | CD209 (DC-SIGN) signaling | |||
15 | CLEC7A/inflammasome pathway | |||
16 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
17 | TRAF6 mediated NF-kB activation | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | DNA Damage Response (only ATM dependent) | |||
3 | SIDS Susceptibility Pathways | |||
4 | TCR Signaling Pathway | |||
5 | Notch Signaling Pathway | |||
6 | TGF Beta Signaling Pathway | |||
7 | Oxidative Stress | |||
8 | IL-4 Signaling Pathway | |||
9 | Apoptosis Modulation by HSP70 | |||
10 | MAPK Signaling Pathway | |||
11 | Myometrial Relaxation and Contraction Pathways | |||
12 | IL1 and megakaryotyces in obesity | |||
13 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
14 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
15 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
16 | Hair Follicle Development: Induction (Part 1 of 3) | |||
17 | Selenium Metabolism and Selenoproteins | |||
18 | Cardiac Hypertrophic Response | |||
19 | Cytosolic sensors of pathogen-associated DNA | |||
20 | Fc epsilon receptor (FCERI) signaling | |||
21 | Transcriptional Regulation of White Adipocyte Differentiation | |||
22 | Signaling by the B Cell Receptor (BCR) | |||
23 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
24 | Structural Pathway of Interleukin 1 (IL-1) | |||
25 | EBV LMP1 signaling | |||
26 | Aryl Hydrocarbon Receptor | |||
27 | T-Cell Receptor and Co-stimulatory Signaling | |||
28 | Apoptosis | |||
29 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
30 | BDNF signaling pathway | |||
31 | Integrated Pancreatic Cancer Pathway | |||
32 | Oncostatin M Signaling Pathway | |||
33 | Corticotropin-releasing hormone | |||
34 | AGE/RAGE pathway | |||
35 | TNF alpha Signaling Pathway | |||
36 | B Cell Receptor Signaling Pathway | |||
37 | TSLP Signaling Pathway | |||
38 | IL17 signaling pathway | |||
39 | Neural Crest Differentiation | |||
40 | TWEAK Signaling Pathway | |||
41 | Leptin signaling pathway | |||
42 | RANKL/RANK Signaling Pathway | |||
43 | Integrated Breast Cancer Pathway | |||
44 | Signalling by NGF | |||
45 | IL-1 signaling pathway | |||
46 | TCR signaling | |||
47 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
48 | Interleukin-1 signaling | |||
49 | Interleukin-1 processing | |||
50 | Apoptosis Modulation and Signaling | |||
51 | Folate Metabolism | |||
52 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
53 | MicroRNAs in cardiomyocyte hypertrophy | |||
54 | Vitamin B12 Metabolism | |||
55 | Selenium Micronutrient Network | |||
56 | Regulation of toll-like receptor signaling pathway | |||
57 | Osteopontin Signaling |